Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

DEA Opts Against Ban on Plant Some Call Opioid Alternative

By R&D Editors | October 13, 2016

The Drug Enforcement Administration has reversed a plan to temporarily ban a plant that some users suggest could be an alternative to powerful and addictive opioid painkillers.

In a notice set to be published Thursday in the Federal Register Thursday, the agency said it was withdrawing its plan to add two psychoactive components of the plant, known as kratom, to the list of the most dangerous drugs.

Advocates urging the DEA to leave kratom off its list of controlled substance have argued that it can be used as a nonaddictive painkiller or can help wean people off other, addictive pain medications. Some lawmakers also complained that the DEA wasn’t being transparent in its effort to ban the plant.

Adding kratom to the DEA’s list of schedule 1 drugs would define the plant as a drug with no currently accepted medical use and a high potential for abuse.

In a letter to the DEA last month, the American Kratom Association said the agency was being overly aggressive in categorizing kratom with other dangerous and highly addictive drugs, including a variety of synthetic drug compounds including synthetic marijuana and “bath salts.”

The association and the Botanical Education Alliance applauded the DEA’s reversal.

“Kratom is not an opiate. It is not addictive,” the groups said. “There is simply no basis whatsoever for the DEA to criminalize or regulate the responsible use by consumers of this product at a time when every federal effort targeting drugs should be focused on the ongoing scourge human of opioid addiction and death.”

Including kratom on the list of drugs that includes marijuana, heroin and LSD, would ban not only its use but likely strictly limit scientific studies for a possible medical use. Such a move would ban the plant for at least two years.

The drug agency said it will now wait for a recommendation from the Food and Drug Administration and take more comments from the public before deciding on kratom’s fate. The public has until Dec. 1 to comment.

For now that means that kratom, a little known plant native to Southeast Asia, remains legal under federal law. Six states, however, have opted to ban kratom or its components.

___

Associated Press writer Geoff Mulvihill in Haddonfield, N.J., contributed to this report.

___

 

Related Articles Read More >

Novel mass spectrometry solution simplifies insight gathering into macromolecular complexes
ENPICOM launches display solution to accelerate antibody selection while maximizing precision
Thermo Fisher Scientific autoimmune-testing instruments now available in the U.S.
Thermo Fisher Scientific and Qatar Genome Program partner to advance precision medicine 
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars